Montreal Heart Institute

Running trials

• Recruiting

  An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

  NCT07426419· Phase 1/2· Affinia Therapeutics· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source

• Recruiting

  Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial

  NCT07524335· Phase 3· Montreal Heart Institute· Source

• Recruiting

  Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation

  NCT07462910· French Cardiology Society· Source

• Recruiting

  Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

  NCT07257198· Phase 3· Montreal Heart Institute· Source

• Recruiting

  Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

  NCT07272902· Nova Scotia Health Authority· Source

• Recruiting

  Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation

  NCT05450328· Phase 2· Montreal Heart Institute· Source

• Recruiting

  BoxX-NoAF Clinical Trial

  NCT06989775· AtriCure, Inc.· Source

• Recruiting

  Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

  NCT07175428· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT

  NCT05337241· Thermedical, Inc.· Source

• Active, not recruiting

  Combined Pulsed Field and Radiofrequency Energy for Ablation of Ventricular Tachycardia

  NCT06816368· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

  NCT07001800· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Not yet recruiting

  Vitamin K and Cognition in Coronary Heart Disease (NutriCog)

  NCT06855953· Montreal Heart Institute· Source

• Recruiting

  Prevail Global Study

  NCT06535854· Medtronic Vascular· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

• Active, not recruiting

  In Vivo Quantitative Mapping of Mitochondrial Cardiac Membrane Potential in Heart Failure

  NCT07087210· Matthieu Pelletier-Galarneau, MD MSc· Source

• Active, not recruiting

  Abbott Medical - VERITAS Study

  NCT06707688· Abbott Medical Devices· Source

• Recruiting

  PULSED AF Post-Approval Study

  NCT06578104· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  Pericardiotomy in Cardiac Surgery

  NCT06486636· Population Health Research Institute· Source

• Active, not recruiting

  Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

  NCT06492291· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Lipid Testing After Myocardial Infarction at the Montreal Heart Institute

  NCT06388668· Montreal Heart Institute· Source

• Recruiting

  Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study

  NCT06249269· Ratika Parkash· Source

• Recruiting

  RAFT - Pace &Ablate

  NCT06299514· Habib Khan· Source

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

• Enrolling by invitation

  ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

  NCT05932615· Abbott Medical Devices· Source

• Recruiting

  Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure

  NCT05859048· Cardiology Research UBC· Source

• Recruiting

  END - VT Cohort Study

  NCT05835791· Nova Scotia Health Authority· Source

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

• Active, not recruiting

  Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

  NCT05598333· Phase 2· AskBio Inc· Source

• Active, not recruiting

  Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

  NCT06008756· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  CTSN Embolic Protection Trial

  NCT06027788· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  Left vs Left Randomized Clinical Trial

  NCT05650658· Baylor College of Medicine· Source

• Active, not recruiting

  Cryoablation for Monomorphic Ventricular Tachycardia

  NCT05675865· Adagio Medical· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Recruiting

  The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

  NCT05427370· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II

  NCT05702463· Phase 1· Montreal Heart Institute· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation

  NCT05511389· McMaster University· Source

• Recruiting

  Aggressive Smoking Cessation Trial (ASAP)

  NCT05257629· Phase 3· Sir Mortimer B. Davis - Jewish General Hospital· Source

• Active, not recruiting

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

  NCT05478304· AtriCure, Inc.· Source

• Recruiting

  COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

  NCT05633810· Phase 3· Montreal Heart Institute· Source

• Active, not recruiting

  Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  NCT05069558· Occlutech International AB· Source

• Recruiting

  Home-based Heat Therapy for Type 2 Diabetes

  NCT05269589· Montreal Heart Institute· Source

• Recruiting

  Comparing the Effects of Combining Cognitive and Physical Exercise Training on Cognition, and Cerebral Blood Flow Regulation in Men and Women With Chronic Heart Failure

  NCT04970888· Montreal Heart Institute· Source

Showing 50 of 78.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation11 recruiting
• Heart failure11 recruiting
• Coronary artery disease9 recruiting
• Aortic stenosis4 recruiting
• Stroke3 recruiting
• Type 2 diabetes3 recruiting
• Ventricular tachycardia3 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Obesity2 recruiting
• Sarcoidosis2 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Dilated cardiomyopathy1 recruiting

Closed trials

• Completed

  DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid

  NCT07391358· Montreal Heart Institute· Source

• Completed

  Pulsed Field or Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation in Heart Failure

  NCT07181291· St. Josefs-Hospital Wiesbaden GmbH· Source

• Withdrawn

  Multidisciplinary Approach for High-risk Patients Leading to Early Diagnosis of Canadians With Heart Failure

  NCT05860608· Montreal Heart Institute· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

  NCT06450366· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  NCT06272981· Biosense Webster, Inc.· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  Portable Oxygen Concentrator in Non-hospitalized Patients With Chronic Heart Failure

  NCT05719363· Inogen Inc.· Source

• Completed

  A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator

  NCT05971693· Biosense Webster, Inc.· Source

• Completed

  A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

  NCT05952869· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  NCT05118893· Anthony Tang· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Home-Based Exercise in Primary Progressive Aphasia (HEPPA)

  NCT06181500· Montreal Heart Institute· Source

• Completed

  Optina Eye to Heart Connection

  NCT05199428· Optina Diagnostics Inc.· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Individualized Exercise Training Based on the Heart Rate Variability in Coronary Heart Disease Patient

  NCT04971707· Montreal Heart Institute· Source

• Completed

  RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

  NCT04485195· Phase 4· Ottawa Hospital Research Institute· Source

• Completed

  Quercetin in Coronary Artery By-pass Surgery

  NCT04907253· Phase 2· Montreal Heart Institute· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source

• Completed

  Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE

  NCT03488420· Montreal Heart Institute· Source

• Terminated

  Transcatheter Mitral Valve Repair for the Treatment of Mitral Valve Regurgitation In Heart Failure (The EVOLVE-MR Trial)

  NCT03891823· Montreal Heart Institute· Source

• Completed

  DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation

  NCT03643224· Medtronic Cardiac Ablation Solutions· Source

• Completed

  Confirm Rx Insertable Cardiac Monitor SMART Registry

  NCT03505801· Abbott Medical Devices· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  VEST Venous Graft External Support Pivotal Study

  NCT03209609· Vascular Graft Solutions Ltd.· Source

• Completed

  Antiarrhythmics or Ablation for Ventricular Tachycardia 2

  NCT02830360· Phase 4· John Sapp· Source

• Completed

  AMPLATZER™ Amulet™ LAA Occluder Trial

  NCT02879448· Abbott Medical Devices· Source

• Completed

  Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248· Phase 4· Population Health Research Institute· Source

• Terminated

  Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

  NCT02387229· Phase 3· Montreal Heart Institute· Source

• Completed

  Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation

  NCT01994252· Ottawa Heart Institute Research Corporation· Source

• Completed

  Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  NCT00673842· Phase 3· University of Calgary· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation82 works · 32 trials
• Congenital heart disease21 works · 0 trials
• Hypertrophic cardiomyopathy11 works · 4 trials
• Vascular dementia8 works · 0 trials